FRESH-PEF56-en
The French Gaucher disease registry
FGDR
| Name | Country code |
|---|---|
| France | fr |
['Clinical data','Paraclinical data (non-biological)','Paraclinical data (non-biological) : Imaging','Biological data','Socio-demographic data']
Individuals
| Topic | Vocabulary |
|---|---|
| Hematology | health theme |
| Internal medicine | health theme |
| Rheumatology | health theme |
| Sphingolipidosis | cim-11 |
| Biological determinants: Genetic predisposition | health determinant |
| Biological determinants | health determinant |
{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Infant, Newborn (birth to 28 days)","concept":{"vocab":"MeSH","vocabURI":"D007231"}},{"value":"Infant (28 days to 2 years)","concept":{"vocab":"MeSH","vocabURI":"D007223"}},{"value":"Child, Preschool (2 to 5 years)","concept":{"vocab":"MeSH","vocabURI":"D002675"}},{"value":"Child (6 to 12 years)","concept":{"vocab":"MeSH","vocabURI":"D002648"}},{"value":"Adolescent (13 to 18 years)","concept":{"vocab":"MeSH","vocabURI":"D000293"}},{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"All of the patients diagnosed and/or followed for Gaucher's disease over all of France. Gaucher's disease is confirmed by the dosage of the enzyme activity of the glucocerebrosidase.","clusion_E":""}
| Name |
|---|
| Nadia;BELMATOUG |
| Jérôme;STIRNEMANN |
| Name | Role |
|---|---|
| ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP) | sponsor |
| Name |
|---|
| ASSOC VAINCRE LES MALADIES LYSOSOMALES (VML) |
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) |
| SANTE PUBLIQUE FRANCE |
| Agency name |
|---|
| CNIL |
['']
['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']
Access on specific project only
Observational Study
| Start | End |
|---|---|
| 1991-01-01 | 3000-01-01 |
Access subject to authorization from the scientific board of the registry, formed by the members of the Evaluation Committee of the Treatment for Gaucher's disease
{"value":"Restricted access","extLink":[{"title":"COAR","uri":"http://purl.org/coar/access_right/c_16ec"}]}
| Name | |
|---|---|
| Nadia;BELMATOUG | nadia.belmatoug@aphp.fr |
| Jérôme;STIRNEMANN | jerome.stirnemann@hug.ch |